Figure 3

Percentages of tiotropium-treated patients achieving the minimum clinically important difference (MCID) for transition dyspnoea index (TDI) in INHANCE[9], INTENSITY[11]and other studies in which tiotropium was the primary treatment of investigation. *Includes assessments made at 13 weeks; ^†Includes assessments made at 25 weeks; ^‡Precise value is not given (values stated as range of 42–47% across all timepoints).